Viewing results 101-125 of 133


e-Therapeutics expects first data from new drug trials this year - UPDATE

Drug discovery and development company e-Therapeutics expects to see the first findings from its new programme of clinical trials before the end of this year....

on 05/22/2012

Xenetic Biosciences, African Medical Investments and e-Therapeutics to appear at Proactive Investors One2One Forum

We have an exciting line-up of companies at the Proactive Investors One2One Forum in London on Tuesday (November 8), which has attracted an incredible amount of interest. So this is a call to arms. If you haven't signed up now do so soon to avoid disappointment. Appearing are Xenetic Biosciences, African Medical Investments......

on 11/07/2011

e-Therapeutics: 2012 represents key year for the business

The firm is looking to generate a flow of data from four drugs that it is putting through Phase I and Phase II trials next year and in 2013...

on 10/19/2011

E-Therapeutics platform technology the main reason to invest in the stock, says Panmure's Neophytou

City broker Panmure Gordon this morning repeated its buy recommendation on e-Therapuetics after the prelims yesterday, although tweaked its price target down a little....

on 07/26/2011

E-Therapeutics chief executive excited by potential of cancer drug

Professor Malcolm Young today spoke of his hopes for the cancer treatment being developed by e-Therapeutics as part of full-funded programme to unlock the potential of four drug candidates....

on 07/25/2011

E-Therapeutics expects to generate a "wealth of data" from clinical trials

E-Therapeutics expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates. This pipeline was identified using a platform called network pharmacology and spans cancer, infections and psychiatry. ...

on 07/25/2011

e-Therapeutics CEO Young 'stunned' by strong backing for cash call

The Newcastle-based drug developer had been expected to come to the market for £4-5 million. Instead it is raising £17.6 million from six big investors, which will help it develop four drug candidates. In an interview, CEO Malcolm Young tells Proactive Investors how surprised he was: "Everybody we approached......

on 02/15/2011